Hai Zheng Pharmaceuticals: Intends to list 43 million yuan for the transfer of 100% equity of its wholly-owned subsidiary.

Hai Zheng Pharmaceutical announced that the company has submitted an application for listing of the transfer of 100% equity of the provincial pharmaceutical company to the Taizhou Equity Exchange on November 10, 2025. The official listing period is from November 11, 2025 to December 8, 2025. The assessed value of 100% equity of the provincial pharmaceutical company is 392 million yuan, and the minimum price for public listing is proposed to be 430 million yuan.